**EVOLVING TRENDS IN HPV VACCINATION IN INDIA AND THE WORLD**

**Zeba Khanam1, Nidhi Gupta2**

1Assistant Professor, 2Associate Professor

Department of Obstetrics and Gynaecology, Hamdard Institute of Medical Sciences and Research and HAHC Hospital, New Delhi-62

**INTRODUCTION**

Cervical cancer has been a concern of mankind for a long time. Research into the risk factors and aetiology of cervical cancer began as early as the 1840s. However, it took nearly a century before cervical cancer was found to be directly related to increased frequency of intercourse, childbirth, and sexual partners. The earliest pathogen implicated in the development of cervical cancer was the herpes simplex virus. Although some researchers at the time were able to demonstrate the presence of antibodies against the virus in sera from cervical cancer patients, no plausible explanation for this association was found.

In the 1970s, German virologist Harald zur Hausen discovered that the papillomavirus caused genital warts in cattle, some of whom later died of genital cancer. He postulated that papillomavirus infection could also cause genital warts and cancer in humans. A decade later, in 1983, Hausen and Gissmann isolated papillomavirus DNA from HeLa cells. HeLa cells were the first immortal cell lines to be cultivated in vitro. The name HeLa derives from the initials of Henirietta Lacks, an African American who died of cervical cancer in 1951 after providing samples of cervical tissue. Since then, the HeLa cells have been used in the formulation of various chemotherapeutic drugs and vaccines. Hausen showed that the papilloma virus DNA isolated from HeLa cells did not resemble that obtained from genital warts. He named this pappiloma strain as the ‘Human papilloma virus-16’ or ‘HPV-16’.

Around the same time, another immunologist, Frazer, who was studying HPV infection in immunocompromised patients, had made ties with Hausen. In the years that followed, Frazer demonstrated that certain high-risk HPV (hrHPV) strains are also responsible for causing anorectal dysplasia, a precursor to anorectal cancer.1

For the ground breaking discovery of the HPV as a cause of cervical cancer, Hausen was later awarded the Nobel Prize in medicine in 2008.

**THE HUMAN PAPILLOMA VIRUS**

**hrHPV and lrHPV strains**

HPV is a double-stranded DNA virus that belongs to the Paillomaviridae family. Today, more than 100 different types of HPV strains are known. The alphavirus HPV strains with high oncogenic potential are referred to as high-risk HPV (hrHPV). Those that cause benign lesions are called low-risk HPV (lrHPV).

About 95% of cervical cancers are caused by the human papillomavirus (HPV). Notably, more than 70% of all cervical cancers, 90% of all anal cancers, and a majority of vulva, vaginal, and penile cancers are caused by hrHPV strains 16 and 18. Another 20% of cervical cancer cases are attributed to the five hrHPV strains, namely 31, 33, 45, 52, and 58. The lrHPV strains are mainly responsible for oroanogenital warts in both sexes. (**Table.1)**

**Table 1 Important hrHPV and lrHPV strains**

|  |  |  |
| --- | --- | --- |
|  | **HPV strains** | **Most common strains** |
| Low risk  | 6, 11, 42, 43, 44 | 6 and 11 |
| High risk  | 16, 18, 33, 35, 45,58 | 16 followed by 18  |

**PATHOGENESIS OF CERVICAL CANCER**

The HPV virus is sexually transmitted and infects more than 80% of men and women early in their reproductive lives. However, most (95%) men and women are able to clear the virus within the first two years after infection. Because of this, a decrease in the prevalence rate of HPV infection is observed after the age of 35. Unfortunately, about 10 to 20% of women remain persistently infected with HPV. Such women are at increasing risk of developing invasive cervical cancer within the next 15 to 20 years if they have a competent immune system, and much sooner within 5 to 10 years if their immune systems are compromised.

**Key molecular events in persistent HPV infection**

The HPV genome contains three important regions: the long control region (LCR), the early (E) region and the late (L) region. The LCR regulates the expression and replication of genes; the protein encoded by the E region is necessary for genetic expression, replication and survival of HPV; The L region encodes HPV structural proteins. The two major hrHPV proteins responsible for persistent infection and tumor progression are the E6 and E7. These alter the host’s cell cycle by inactivating the tumor suppressor proteins p53 and pRB, respectively. **Figure.1**

In women with an intact immune system, the Toll-like receptors (TLRs) on the surface of macrophages, Langerhans cells, and natural killer cells play an important role in establishing an innate immune response against HPV infection. Binding of the TLRs to the viral components activates the nuclear factor kappa B transcription factor and interferon response factor-3 (IFR-3). This leads to increased production of pro-inflammatory cytokines and viral clearance. The TLRs also indirectly activate MHC (major histocompatibility complex) expression on the antigen presenting cells and trigger adaptive immunity. The hrHPV E5 protein inhibits the expression of the MHC class I molecule and decreases the production of antiviral cytokines. The E6 protein also inactivates TLRs and promotes immune evasion.2

It can be seen that the TLR gene expression increases with the severity of the cervical lesion. This is because overexpression of oncoproteins E5 and E7 downregulates TLR-9 expression and impairs the release of antiviral cytokines. The end result is resistance to host immunity and persistent infection.2 (**Figure.1**)

**Figure.1** Molecular mechanism of persistent cervical infection with HPV

\*\* Pathway leading to persistent HPV infection; INF-γ, interferon-gamma; TGF α/β, Tumor growth factor alpha/beta; IL, interleukin; NF-Kb, Nuclear factor kappa B; TLRs, Toll like receptors; IFR-3, interferon response factor-3; hrHHPV, high risk HPV

**WHY A VACCINE?**

Cervical cancer is the fourth most common cancer in women worldwide. It is responsible for 600,000 new cancer cases and 300,000 cancer-related deaths each year. Low- and middle-income countries carry the highest (90%) global annual burden of cervical cancer and related mortality.3-5

Today we know that cervical cancer can be prevented and millions of lives saved. However, the foundation for this must be laid on two main prevention strategies; primary prevention against HPV infection and secondary prevention for early detection of the disease.

**THE HPV VACCINE**

The quest for an HPV vaccine began with a series of murine experiments employing transgenic HPV oncoproteins. However, it was not until 1989 at Cambridge University that Fraser met a Chinese virologist, Dr Jian Zhou, who had a similar interest in HPV. Little was known that this alliance would write a new history. In 1990 Jian and his partner Xiao-Yi Sun moved into Fraser’s laboratory in Brisbane and synthesized a vaccine from viral capsids (or virus-like particles/VLPs). They applied for its patency in 1991, but received it more than a decade later, in 2006.1

After 2006, most of the development and production of HPV vaccine was taken over by two pharmaceutical giants: Merck and GSK. The first HPV vaccine to receive FDA approval was Merck’s *Gardasil* in 2006. Three years later, in 2009, the FDA approved GSK’s bivalent *Cervarix.* The first nonavalent vaccine, *Gardasil-9*, was approved by the FDA in 2014. All of these vaccines proved to be highly immunogenic and were able to induce long lasting immunity against HPV infection in HPV naïve men (90-100%) and women (80-90%). (**Table.2**)

**Table.2 The three major types of HPV vaccines**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Bivalent vaccine** | **Quadrivalent vaccine** | **Nonavalent vaccine** |
| **HPV subtype coverage** | 16, 18 | 6, 11, 16,18  | 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| **Immunogenicity in HPV naïve person** | Females- 93% -100%Males- 99% -100% |
| **Brand**  | *Cervarix* (GSK)*Cecolin* (Xiamen Innovax Biotech Co ltd)  | *Gardasil* (Merck)*Cervavac* (Serum Institute of India)  | *Gardasil-9* (Merck)  |
| **Drug approval**  | *Cervarix* was approved by the FDA in 2009. Not approved in India by the CDSCO | *Gardasil* was approved by FDA in 2006.Not approved in India by the CDSCO | *Gardasil-9* was approved by the FDA in 2014.  |
| **Availability**  | Available in India. Not available in US. China prepares its own bivalent vaccine that is prequalified by the WHO for use in resource-limited settings under the brand of *Cecolin*.  | Available in India. Not available in US.  | Available in India and US.  |
| **Indication**  | For the primary prevention of cervical, vaginal, vulval, oropharyngeal, penile and anal cancers.  | For the primary prevention of cervical, vaginal, vulval, oropharyngeal, penile and anal cancers.For the prevention of anogenital warts.  | For the primary prevention of cervical, vaginal, vulval, oropharyngeal, penile, anal cancers and anogenital dysplastic lesions. For the prevention of anogenital warts.  |
| **Price in the Indian market (INR)**  | *Cervarix*- INR 2270 for a prefilled dose containing 0.5 mL vaccine suspension. | *Gardasil*- INR 3927 for a prefilled dose containing 0.5 mL of vaccine suspension. *Cervavac*- INR 2000 for two doses.  | *Gardasil-9*- INR 10340.75 for a prefilled dose containing 0.5 mL vaccine suspension. |

CDSCO, Central Drug Standard Control Organisation; FDA, Food and Drug Administration

**Is vaccination required for boys and men?**

Male immunisation can reduce the rate of anogenital cancers in both sexes through herd immunity.6 However, this may not be cost effective, particularly in low resource settings.

**When to vaccinate?**

* Vaccination should be ideally be initiated prior to first sexual contact.
* HPV vaccination does not treat or increase the clearance rate of the viral infection. Nevertheless, vaccination can prevent infection with other HPV strains in sexually active men and women, although the benefit is far less than in HPV naïve persons.
* The **US Advisory Committee on Immunisation Practices (ACIP)**, along with the **American College of Obstetricians and Gynecologists (ACOG)**, the **American Society of Clinical Oncology (ASCO)**, the **Centre for Disease Control (CDC),** the **American Academy of Paediatrics (AAP),** the **American Academy of Family Physicians (AAFP),** and the **American Cancer Society (ACS)** agree to initiate HPV vaccination as follows:
	+ 11-12 years of age: Initiate HPV vaccine as routine vaccination; the vaccine can be started as early as 9 years of age.
	+ 13 to 26 years of age: Initiate vaccine as Catch-Up vaccination for those who have never been vaccinated or who have received an incomplete dose.
	+ ≥27 years and up to 45 years: Initiating a Catch-Up vaccination is not recommended because the benefit and cost-effectiveness of vaccination in preventing cervical cancer decreases with age. However, the AICP states that the decision to vaccinate can be individualised.7-13
* **WHO and ASCO recommendations on HPV vaccination in resource poor settings:**
	+ The ‘primary vaccine targets’ should be girls aged 9-14 years.
	+ Local public health programs should only recommend vaccinating older females when it is logistically and financially feasible and only when it does not divert resources from the primary target group or cervical cancer screening.9,13
* **The Indian Academy of Paediatrics (IAP) recommendations on vaccination schedule14:**

|  |  |  |
| --- | --- | --- |
|  | **Vaccine dose** | **Vaccine schedule** |
| Girls aged 9-14 year- *Preferred target vaccination*  | 2 doses  | Bivalent/Quadrivalent/Nonavalent  | Dose 1: 0 monthDose 2: 6 months or between 5 and 15 months of the first dose |
| Girls aged 15-26 years- *Catch-Up vaccination*  | 3 doses  |  Bivalent  | Dose 1: 0 monthDose 2: 1 monthDose 3: 6 months |
|  |  | Quadrivalent/Nonavalent  | Dose-1: 0 monthDose-2: 2 monthsDose-3: 6 months |
| Older women 27 to 45 years of age  | 3 doses  | Similar to catch-up vaccination |

**Which is the best vaccine?**

There is no consensus on the best HPV vaccine. In fact, the nonavalent and quadrivalent vaccines show broader disease coverage in both sexes.

In general, the same vaccine should be used to complete a vaccination series. However, if it is not known which vaccine was administered or if the patient is known to have been vaccinated with a nonavalent vaccine, another vaccine may be used.

**When not to administer the vaccine?**

Hypersensitivity to the vaccine or its components.

**Vaccination in pre-existing HPV related disease**

* In women with a positive history of genital warts, positive HPV testing or abnormal cytology results, HPV vaccination should be based on age specific recommendations.
* These women should be advised that the vaccine does not affect the rate of progression of a preexisting cervical dysplastic or neoplastic lesion and hence cannot cure the disease.

**How to administer the vaccine?**

* 0.5 mL of the vaccine suspension is administered intramuscularly in the deltoid muscle of the arm.
* The vaccine may be concurrently administered with tetanus, acellular pertussis, diphtheria, or inactivated polio virus vaccine.

**What is not required when prescribing an HPV vaccine?**

* Pre-vaccination pregnancy testing
* Pre-vaccination HPV DNA testing
* Post-vaccination anti HPV antibody titre estimation.
* Booster vaccination or initiating vaccination after completion of a vaccination series- There is no evidence that booster vaccination increases protective immunity. This also applies to patients who have completed their vaccination schedule with either a bivalent or quadrivalent vaccine and are considering revaccination with the nonavalent vaccine.

**What is the role of cervical cancer screening in women who have already been vaccinated against HPV infection?**

HPV vaccination should not alter the frequency and schedule of cervical cancer screening.

**HPV vaccination during pregnancy and lactation**

* For safety reasons, HPV vaccination is not recommended during pregnancy. However, if the vaccine was accidentally administered, this is not an indication of termination of pregnancy. The rest of the vaccine series should be completed after delivery.
* HPV vaccines are safe for breastfeeding women.

**Vaccination in health care workers exposed to HPV infection**

Healthcare workers can be exposed to nasal and oropharyngeal HPV infection from fumes generated during the surgical removal or ablation of HPV-related lesions.

The American Society of Colposcopy and Cervical Pathology recommends that healthcare workers who are regularly exposed to HPV should be vaccinated.15

**What should be done if a vaccine dose is missed?**

If the vaccination series is interrupted, the vaccination can be resumed without restarting the entire vaccination series, regardless of the duration of interruption.

**What are the side effects of HPV vaccine?**

HPV vaccine contains virus like particles that mimic the viral capsid protein. The vaccine contains no HPV genetic material and is considered extremely safe. However, due to the occurrence of syncope attacks after vaccination, patients are advised to lie down for at least 15 minutes after the injection.

**GLOBAL STANDS ON HPV VACCINATION**

**The 90-70-90 target**

In August 2020, the WHO called for the elimination of cervical cancer by 2030 as part of its "Global Cervical Cancer Elimination Initiative". This would roughly correspond to a reduction in the cervical cancer rate to 4 per 100,000 women. To this end, WHO has set the 90-70-90 target for countries. The goal is to vaccinate 90% of girls by age 15, screen 70% of women for cervical cancer by age 35 and then by age 45, and to treat 90% of women with cervical precancerous or invasive lesions.16

**Taskforce on Cervical Cancer Elimination in the Commonwealth**

The Commonwealth accounts for about 40% of the global incidence rates for cervical cancer and associated mortality. No wonder, India is a major contributor. An international Taskforce on Cervical Cancer Elimination in the Commonwealth was established by the Commonwealth Secretariat and the Union for the International Cancer Control (UICC) in 2021 with the aim of stepping up efforts towards prevention and treatment of cervical cancer in the commonwealth region and achieve cancer elimination goals, put forward by the WHO Global Cervical Cancer Elimination Strategy.

**WHO SAGE committee opinion on vaccine schedule**

In April 2022, the WHO Strategic Advisory Group of Experts (SAGE) on immunization found evidence of similar efficacy of the single-dose HPV vaccine compared to the 2- or 3-dose HPV vaccination schedules. The SAGE concluded that a single-dose HPV vaccine offered solid protection against the virus and viewed it as a game-changer in the fight against cancer.16 (**Table.3**)

**Table.3 HPV vaccination schedule as proposed by the WHO SAGE committee**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Girls aged 9-14 years**  | **Girls aged 15-20 years**  | **Girls aged over 21 years**  | **Immunocompromised females (including HIV infected)** |
| **Number of doses**  | One or two doses  | One or two doses  | Two doses, with a minimum of 6-month interval  | Minimum of two doses.Preferred- Three doses |

**The Big Catch-Up Initiative**

In December 2022, the WHO reiterated its position on the single-dose schedule. This newly recommended schedule promised an expansion in vaccination coverage and a reduction in morbidity and morbidity associated with HPV infection. In April 2023, WHO, in collaboration with UNICEF endorsed the ‘The Big Catch-up’ initiative, which is a targeted global approach to increase vaccination rates in children after a decline in vaccination coverage rates during the COVID-19 pandemic.17

**INDIA’S STAND ON HPV VACCINATION**

**India’s burden of cervical cancer**

While African countries lead in cervical cancer incidence rates, India fares no better; the incidence rate and annual cancer-related mortality rate for cervical cancer in India are 6-29% and 9.1%, respectively. In fact, cancer cervix is the second leading cause of cancer-related death in India. The district of Papumpare in the state of Arunachal Pradesh has the highest incidence rate (27.7%) for cervical cancer in all of Asia. Adding to this apathy, immunization coverage and cervical cancer screening rates in India are a meagre <1% and <2%, respectively.18

**A tumulous path to vaccination**

Countries like United Kingdom, and Denmark have achieved high HPV vaccination coverage (>60%). This is secondary to the inclusion of the vaccine in their national immunisation programme. In January 2023, India rolled out first of the three phases of the nationwide immunisation programme as recommended by the National Technical Advisory Group for Immunisation (NTAGI).19 This move was urgently needed and far delayed compared to its neighbours, Bhutan, Sri Lanka, Thailand, and the Maldives, which established their national HPV immunisation programmes years ago.

The vaccines *Gardasil* and *Cervarix* were licenced for use in India back in 2008. Soon the international NGO Programme for Global Health Organisation (PATH) in collaboration with the Government of Andhra Pradesh and Gujrat and the Indian Council of Medical Research (ICMR) launched a project entitled, ‘A post-licensure observational study of HPV vaccination: Demonstration Project’ to test their effectiveness and tolerability. This project was part of a larger global project, ‘HPV vaccine: Evidence for Impact’. The vaccines used in the PATH’s project were donated by pharmaceutical companies, GSK and MSD. Unfortunately, the project was halted prematurely due to seven alleged vaccine-related deaths. However, it turned out that the deaths were unrelated to vaccination. Nonetheless, this was a major setback for HPV vaccination efforts in the country.20

In 2016, Delhi became the first Indian state to vaccinate school girls. A year later, the Punjab government launched a vaccination campaign in two districts (Bathinda and Mansa). In 2018, Sikkim became the third state to start an HPV vaccination program with the goal of targeting girls aged 9 to 14 in 1,166 schools. In 2022, the Serum Institute of India, in collaboration with the Department of Biotechnology of the Government of India, launched *Ceravac* after receiving the Drug Controller General of India. *Cervavac* is the first indigenous vaccine and it promises to overcome rural-urban vaccine inequity in the country.

**The NTAGI recommendations for vaccinating school girls21**

In 2023, the Government of India National Technical Advisory Group for Immunisation (NTAGI) recommended following:

* The *inclusion of the HPV vaccination in the Universal Immunisation Programme (UIP)* as a *one-time Catch-Up Vaccination* for adolescent girls aged 9 to 14 followed by *routine vaccination of girls at 9 years of age*.
* School going adolescent females will be vaccinated using a Graded-approach i.e Between 5th and 10th school grades.
* Girls who miss the school health vaccination campaign as well as those who do not go to school, will be vaccinated in health facilities or through community outreach programmes and mobile health campaigns.

In line with the NTAGI recommendations, the Government of India, has proposed following plan of action:

* The state governments and union territories will ensure smooth HPV vaccination campaigns in schools.
* The District Educational Officer will assist the District Immunisation Officer in vaccination drives. The District Task Force on Immunisation will oversee the campaign and report directly to District Magistrate.
* One person will be appointed from each school as the nodal person. He/she will coordinate vaccination activities and collate the number of girls in the school.
* The registration, recording and reporting of vaccination data should done through the U-WIN software application.
* Special parent teacher meet will be organised to spread awareness about cervical cancer and the HPV vaccine.
* UpToDate list of all types of schools (UDISE+) should be created for all blocks for microplanning.
* GIS mapping of the schools should be done to district immunisation officers for developing micro plans so that all schools are covered.
* Vaccination camps should be scheduled on days other than holidays and vacations.

**CONCLUSION**

India is lagging behind the goal of eliminating cervical cancer by 2030. The launch of Cervavac and the roll out of a phased HPV vaccination program are the much-needed welcome steps by the government towards a cervical cancer free India. However, much remains to be done. The masses need to be made aware of this preventable and curable cancer. The government needs to address logistical and infrastructural deficiencies that create rural-urban inequities and sponsor a statewide cervical cancer screening programme to identify at risk women.

**REFERENCES**

1. Frazer I H. The HPV vaccine story. ACS Pharmacol Transl Sci. 2019;2:210-12. doi: 10.1021/acsptsci.9b00032
2. Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key Molecular Events in Cervical Cancer Development. Medicina (Kaunas). 2019 Jul 17;55(7):384. doi: 10.3390/medicina55070384. PMID: 31319555; PMCID: PMC6681523.
3. World Health Organisation. Cervical cancer [Internet]. Geneva: WHO; 2022 [cited 2023 August 27]. Available from: https://www.who.int/health-topics/cervical-cancer#tab=tab\_1
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
5. Indian Council of Medical Research-National Centre for Disease Informatics and Research. Report of National Cancer Registry Programme [Internet]. Bengaluru: ICMR-NCDIR;2020 [cited 2023 August 28]. Available from: <https://www.ncdirindia.org/All_Reports/Report_2020/default.aspx>
6. [Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394:497.](https://www.uptodate.com/contents/human-papillomavirus-vaccination/abstract/8)
7. [Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1.](https://www.uptodate.com/contents/human-papillomavirus-vaccination/abstract/17)
8. [American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809. Obstet Gynecol 2020; 136:e15. Reaffirmed 2023.](https://www.uptodate.com/contents/human-papillomavirus-vaccination/abstract/26)
9. [Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin 2020; 70:274.](https://www.uptodate.com/contents/human-papillomavirus-vaccination/abstract/30)
10. HPV Vaccine Schedule and Dosing. Centres for Disease Control and Prevention. https://www.cdc.gov/hpv/hcp/schedules-recommendations.html (Accessed on January 16, 2023).
11. American Academy of Paediatrics. Human Papillomaviruses. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd edition, Kimberlin DW, Barnet ED, Lynfield R, Sawyer MH (Eds), American Academy of Paediatrics, Elk Grove, IL 2021.
12. [Quinlan JD. Human Papillomavirus: Screening, Testing, and Prevention. Am Fam Physician 2021; 104:152.](https://www.uptodate.com/contents/human-papillomavirus-vaccination/abstract/32)
13. World Health Organisation. WHO updates recommendations on HPV vaccination schedule [Internet]. Geneva:WHO;2022 December 20 [cited 2023 Aug 27]. Available from: <https://www.who.int/news/item/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule>
14. IAP Advisory Committee on Vaccines and Immunisation Practices. Human Papilloma virus vaccines (hpv vaccine) [Internet]. Navi Mumbai: IAP ACVIP; 2020-2021 [cited on 2023 Aug 27]. Available from: https://iapindia.org/pdf/vaccine-information/HPV-VACCINE.pdf
15. American Society for Colposcopy and Cervical Pathology. ASCCP Recommends HPV Vaccination for Providers [Internet]. US:ASCCP;2020 [cited on 2023 Aug 27]. Available from: https://www.asccp.org/hpv-vaccination.
16. [Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin 2020; 70:274.](https://www.uptodate.com/contents/human-papillomavirus-vaccination/abstract/30)
17. World Health Organisation. Human papillomavirus vaccines: WHO position paper [Internet]. Geneva: WHO; 2022 Dec [cited 2023 Aug 27]. Available from: https://www.who.int/publications/i/item/who-wer9750.
18. World Health Organisation. Global partners announce a new effort- ‘The Big Catch-Up’- to vaccinate millions of children and restore immunisation progress lost during the pandemic [Internet]. Geneva:WHO;2023 April 23 [cited 2023 Aug 27]. Available from: <https://www.who.int/news/item/24-04-2023-global-partners-announce-a-new-effort-the-big-catch-up-to-vaccinate-millions-of-children-and-restore-immunization-progress-lost-during-the-pandemic>
19. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in India. Summary Report 10 March 2023. [cited on 2023 August 2023].
20. Burki TK. India rolls out HPV vaccination. Lancet Oncol. 2023 Apr;24(4):e147. doi: 10.1016/S1470-2045(23)00118-3. Epub 2023 Mar 16. PMID: 36934729.
21. HPV vaccination in South Asia: new progress, old challenges. The lancet Oncology. 2022;23(10):p1233. doi:10.1016/S1470-2045(22)00567-8.
22. Press Information Bureau. Ministry of Education. Government of India. Centre urges States to create awareness and take steps for prevention of cervical cancer among girl students [Internet]. Delhi: PIB; 2022 Dec 22 [cited 2023 Aug 23]. Available from: <https://pib.gov.in/PressReleseDetailm.aspx?PRID=1885597>